UMass Medical School and its partners at Boston Children’s Hospital and other academic medical centers have been awarded $20 million from the Centers for Disease Control and Prevention (CDC) to expand their efforts toward preventing another outbreak of Ebola or other highly contagious virus in Liberia
Researchers at UMass Medical School will soon begin a pilot study to explore how a digital pill would allow doctors to monitor patients who do not take their medicine as prescribed in real-time—a major health care problem in the United States.
Marc Freeman, PhD, has developed a new fruit fly model to investigate pathological changes in neurons with neurodegenerative mutations as they age with unprecedented resolution. This powerful new tool has already been used to identify two new genes that play a role in ALS-related neurodegeneration.
Katherine Luzuriaga, MD, will give a talk on eradicating HIV as part of the Fairman Cowan Collegiate Lecture Series on Oct. 15.
A pair of studies in the journal Nature, one by Jeremy Luban, MD, and colleagues in Italy and Switzerland, and the other by Heinrich Gottlinger, MD, PhD, and colleagues; have identified genes that disable HIV-1, suggesting a promising new strategy for battling the virus that causes AIDS.
Few older adults walk on a regular basis even though it’s easy, free and good for their health. A new study by public health researchers at UMass Medical School examines how neighborhood conditions influence walking habits for adults 65 and older.
UMass Medical School cancer biologist Lucio Castilla, PhD, accepted a $250,000 grant from the Hyundai Motor America Hope on Wheels campaign for his research into targeted therapies for pediatric blood cancers at a ceremony on Friday, Sept. 25.
Researchers at UMass Medical School have discovered a new pathway that triggers regeneration of beta cells in the pancreas, a key development that may aid in the development of diabetes treatments.
An important new therapeutic based on discoveries at UMass Medical School’s MassBiologics will be submitted for regulatory approval based on the results of clinical studies conducted by the international pharmaceutical company Merck.
Early findings from a major NIH study appear to show significant cardiovascular benefits from lowering the recommended systolic blood pressure for adults over age 50 at elevated risk for heart disease, but some primary care doctors at UMMS will proceed cautiously before making any changes with their patients.